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Invasive device-associated nosocomial infections of a teaching
hospital in Turkey; four years’ experience
Aslıhan CANDEVİR, Behice KURTARAN, Filiz KİBAR, Emre KARAKOÇ, Hasan Salih Zeki AKSU,
Yeşim TAŞOVA

Aim: To determine our setting's IDAI rates, infecting microorganisms, and their resistance patterns to achieve
standardization and make comparisons among other Turkish and developed country hospitals all over the world.
Materials and methods: The numbers of total patient days, ventilator days, central catheter days and, urinary catheter
days in the ICUs were recorded and IDAI rates were calculated. Clinical specimens were obtained from patients, cultivated
at appropriate culture media, and infecting microorganisms and resistance patterns were determined.
Results: Totally 1450 invasive device-associated infection episodes were determined (16.4% of patients) with a rate of
21.12/1000 days. Ventilator associated pneumonia rate was 22.05/1000 ventilator days and most common microorganism
was Acinetobacter baumannii. Central catheter associated blood stream infection rate was 9.14/1000 central catheter days
and the most common infecting organism was A. baumannii. Catheter associated urinary infection rate was 10.12/1000
urinary catheter days and the most common pathogen was Candida species. MRSA rate decreased from 89.6% in 2006
to 61.8% in 2009 (P < 0.001). ESBL production rates were between 70.7% and 45.6% in Escherichia coli and 66.7% and
55.9% in Klebsiella pneumoniae isolates. Vancomycin resistance among Enterococci was between 34.3% and 21.7% in
these years.
Conclusion: Our hospital infection rates were found to be similar to those of country data but higher than those in
developed nations. Considering the high infection and resistance rates to most of the available antibiotics, it is highly
urgent that infection control measures be taken and more effective antibiotic control policies be adopted.
Key words: Device associated infection, nosocomial, resistance

Türkiye'deki bir hastanenin invazif araç ilişkili enfeksiyon hızları; dört yıllık
deneyim
Amaç: Merkezimizdeki invazif araç ilişkili enfeksiyon hızlarının, etken mikroorganizmaların ve direnç paternlerinin
tespit edilerek standardizasyon sağlanması ve Türkiye ile gelişmiş ülkelerdeki hastaneler ile karşılaştırma yapılması.
Yöntem ve gereç: Yoğun bakımlarda toplam hasta günü, ventilatör günü, santral kateter günü ve üriner kateter günleri
kayıt edildi ve invazif araç ilişkili enfeksiyon hızları hesaplandı. Hastalardan klinik örnekler alınarak uygun ortama ekildi
ve enfekte eden mikroorganizmalar ile direnç paternleri tespit edildi.
Bulgular: Toplam olarak % 16,4 oranında ve 12, 12/1000 hasta gününde 1450 invazif araç ilişkili enfeksiyon tespit
edilmiştir. Ventilatör ilişkili pnömoni hızı 21, 12/1000 ventilatör günü ve en sık görülen patojen Acinetobacter baumannii
idi. Santral kateter ilişkili kan dolaşım enfeksiyonu hızı 9,14/1000 kateter günü ve en sık izole edilen patojen A. baumannii
idi. Kateter ilişkili üriner sistem enfeksiyon hızı ise 10,12/1000 kateter günü ve en sık karşılaşılan patojen Candida türleri
idi. MRSA oranı 2006 yılında % 89.6’dan 2009 yılında % 61.8’e düştü (P < 0,001). ESBL oranları çalışma yıllarında
Escherichia coli’de % 70,7 ve % 45,6 arasında, Klebsiella pneumoniae’de ise % 66,7 ve % 55,9 arasında idi. Enterokok türleri
arasında vankomisin direnci % 34,3 ve % 21,7 arasındaydı.
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Sonuç: Hastanemiz enfeksiyon hızları ülke verileriyle benzer ancak gelişmiş ülkelere oranla yüksek bulundu. Bu yüksek
enfeksiyon hızları ve antimikrobiyallere direnç oranları göz önüne alındığında enfeksiyon kontrol önlemlerine uyumun
acil olarak arttırılması ve daha etkili antibiyotik kontrol politikaları geliştirilmesine ihtiyaç vardır.
Anahtar sözcükler: Araç ilişkili enfeksiyon, direnç, nozokomiyal

Introduction
Healthcare associated infections (HAI) result in
increased mortality, morbidity, and costs (1). The
Centers for Disease Control and Prevention (CDC)
Study of the Efficacy of Nosocomial Infection Control
(SENIC) has shown the efficacy of surveillance in
helping to prevent healthcare acquired infections
(HAIs) (2). Since the majority of the infections occur
in intensive care units (ICU) and invasive deviceassociated infections (IDAIs) represent the greatest
threat in the ICUs, targeted surveillance and
calculation of IDAI rates per 1000 device-days, is used
in hospitals in the US and other developed countries
which allows benchmarking between similar
institutions (3,4). ICUs also are often associated with
resistant microorganisms (5).
There are several reports on invasive deviceassociated infections from Turkey. In this study our
aim was to determine our setting’s IDAI rates,
infecting microorganisms, and their resistance
patterns to achieve standardization and make
comparisons among other Turkish and developed
country hospitals all over the world.
Materials and methods
Setting
Our hospital is a referral hospital with 1020 beds,
in the southern part of Turkey, which receives
significant amount of migration from the southeast.
Targeted surveillance performed at 4 ICU units
started in January 2006; A: 10 bedded traumatic,
general medical and surgical ICU, B: 13 bedded
general medical ICU, C: 16 bedded neurosurgical
ICU, D: 14 bedded pediatric medical and surgical
ICU. The units have 2-4 isolation rooms each. Patient
to nurse ratio is approximately 1:5.
Surveillance
Infection control nurses and doctors visited all the
ICUs regularly. Demographic data consisting of age,
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gender, underlying diseases, etc. were recorded.
Patient records were examined for physical
examination, blood counts, microbiology data,
temperature, and treatment charts. The patient’s
doctors were also consulted. Center for Disease
Control (CDC) definitions for hospital infections
were used for diagnosis (6).
Total patient days, ventilator days, central catheter
days, and urinary catheter days in the ICUs were
recorded. The overall infection rates were calculated
by dividing infection episodes by total patient days,
multiplied by 1000. IDAI rates were calculated by
dividing number of episodes by total device days,
multiplied by 1000. Device utilization rates were also
calculated; dividing device days by total patient days
(7). Four years’ surveillance data of 2006-2009 were
extracted.
Microbiology
Clinical specimens were obtained from patient’s
peripheral blood and from indwelling catheters,
tracheal and bronchial aspirates, and from urinary
catheters. They were cultivated on appropriate culture
media (obtained from bioMérieux, France) (8,9).
At least 2 sets of blood culture bottles were
incubated in BACTEC 9240 (Becton Dickinson
Microbiology System) at 35 °C for 7 days. When there
was a positive culture signal the blood specimens were
added to 5% sheep-blood agar, Chocolate agar,
MacConkey agar, and Sabouraud dextrose agar (SDA)
with antibiotics. SDA media were incubated at 37 °C
for 7 days for fungus. Daily observation was made for
positive culture. If there was a positive culture, Gram
staining for direct microscopic examination was
performed from colony suspensions and
microorganism existence was investigated.
Identification of bacteria and yeast isolates was
performed by using conventional methods and Gram
Positive Identification (GP ID) and Gram Negative
identification (GN ID) cards of the VITEK 2 system
(bioMérieux, France).

A. CANDEVİR, B. KURTARAN, F.KİBAR, E. KARAKOÇ, H. S. Z. AKSU, Y. TAŞOVA

Antimicrobial susceptibilities of the test organisms
were determined using the VITEK 2 system
(bioMérieux, France) according to the manufacturer’s
recommendations. Susceptibility testing was done by
VITEK II system (bioMerieux, France) and API
systems (bioMerieux, France). Clinical Laboratory
Standards (CLSI) were used for interpretation of
antimicrobial resistance patterns (10).
Detection of extended-spectrum beta-lactamase
(ESBL) production was performed using the E-test (AB
BIODISK, Solna, Sweden). The criterion for ESBL
production was at least an 8-fold decrease in the MIC
of ceftazidime with an addition of 4 mg/L clavulanic
acid for K. pneumoniae and E. coli strains (10).
For Staphylococcus spp., susceptibility testing with
the VITEK 2 system was performed. The current
CLSI breakpoints for oxacillin susceptibility were
used: MICs of ≤ 2 mg/L indicated susceptibility, and
MICs of ≥ 4 mg/L indicated resistance.

For Enterococcus spp., determined MICs in the
VITEK 2 system with Antimicrobial Susceptibility
Testing card were confirmed using Vancomycin E-test
strips (AB BIODISK, Solna, Sweden).
Multidrug resistance was defined as resistance to 3
or more groups of antimicrobials: cephalosporins,
aminoglycosides,
quinolones,
piperacillintazobactam, and carbapenems. Extreme drug
resistance was defined as resistance to all antibiotics
available except colistin and tigecycline.
Results
Totally 6834 patients were admitted to our hospital
ICUs; 1450 device-associated infections occurred in
68,425 patient days in 1118 patients with a rate of
16.4% and 21.12 per 1000 patient days. Distribution of
IDAI rates and utilization ratios according to years are
shown in Table 1.

Table 1. Distribution of invasive device-associated infection rates and utilization ratios according to years.
Years

VAP

CA-BSI

CA-UTI

IDAIR*

2006

n /%
dd / rate
DUR

185 / 48.4
7942 / 23.3
46

73 / 19.1
7805 / 9.4
45

124 / 32.5
12,098 / 10.2
70

382
17,283 / 22.20

2007

n /%
dd / rate
DUR

181 / 50.7
7898 / 22.92
44.4

67 / 18.8
7892 / 8.49
44.4

109 / 30.5
13,110 / 8.31
73.7

357
17,783 / 20.08

2008

n /%
dd / rate
DUR

149 / 40
8101 / 18.39
46

77 / 20.6
8119 / 9.48
46

147 / 39.4
12,067 / 12.18
69

373
17,453 / 21.37

2009

n /%
dd / rate
DUR

166 / 49.1
6949 / 23.89
43

66 / 19.5
7149 / 9.23
44

106 / 31.4
10,750 / 9.86
67

338
15,906 / 21.25

Total

n /%
dd / rate
DUR

681 / 47
30,890 / 22.05
45

283 / 19.5
30,965 / 9.14
45

486 / 33.5
48,025 / 10.12
70

1450
68,425 / 21.19

dd: device days, DUR: Device utilization ratio, Rate: Calculated by dividing number of infections by
device days multiplied by 1000, VAP: Ventilator associated pneumonia, CA-BSI: Catheter associated
blood stream infection, CA-UTI: Catheter-associated urinary tract infection
*IDAIR: Invasive device-associated infection rate-Calculated by dividing number of infections by patient
days multiplied by 1000
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Of the device-associated infections, 47% were
ventilator-associated pneumonia (VAP), 19.5% were
central venous catheter-associated blood stream
infections (CA-BSIs), and 33.5% were urinary
catheter-associated urinary tract infections (CAUTIs) (Table 1).
The overall VAP rate was 22.05 per 1000 ventilator
days varying between 18.39 and 23.89 per 1000
ventilator days in different years. Device utilization
ratio (DUR) was 45% overall. The most frequent
isolates were Acinetobacter baumannii 40% (n = 493),
followed by Pseudomonas aeruginosa 18.8% (n = 232),
Staphylococcus aureus 13.8% (n = 170), and Klebsiella
pneumoniae 9.1% (n = 112).
CA-BSI rate was 9.14 per 1000 central venous
catheter days varying in different ICUs between
8.49 and 9.48 per 1000 catheter days. Central
venous catheter utilization ratio was 45% overall.
The most frequently isolated microorganisms were
A. baumannii 19.1% (n = 134), Enterococcus
faecium 10.6% (n = 74), coagulase negative
staphylococci (CNS) 8.4% (n = 59), and S .aureus
8.4% (n = 59).
CA-UTI rate was 10.12 per 1000 urinary catheter
days and varied between 8.31 and 12.18 per 1000
catheter days. Urinary catheter utilization ratio was
70%. The most frequent infecting microorganisms
were Candida spp. 31.6% (n = 284), Escherichia coli
17.9% (n = 161), Enterococcus spp. 8.9% (n = 80), and
K. pneumonia 7.8% (n = 70).
Totally 3269 microorganisms were isolated and
65.3% of these microorganisms were gram negative
and 13.9% were Candida spp. (Table 2). The most
common infecting microorganism was A. baumannii
(25.5%, n = 835), followed by P. aeruginosa (14.2%, n
= 465), K. pneumoniae (8.6%, n = 280), E. coli (8.5%,
n = 279), and S. aureus (8%, n = 260).
The resistance patterns of the selected
microorganisms to antimicrobials are summarized in
Table 3. Resistance to antimicrobials in Acinetobacter
and Pseudomonas strains increased where MRSA rate
decreased significantly from 89.6% to 61.8% (P <
0.001).
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Discussion
Most of the ICU acquired infections are related to
invasive devices and these infections are associated
with isolates of resistant microorganisms. In order to
decrease the healthcare associated infections,
surveillance and particularly the surveillance of
invasive device-associated infections is essential. Our
overall infection rate was similar to that of hospitals in
developing countries and Turkey; 14.7% and 22.5
infections per 1000 ICU days in a multi-center study
by Rosenthal et al. involving the rates of 8 developing
countries (11), and 38.3% and 33.9 IDAI per 1000
patient days (INICC Turkish branch) in Leblebicioğlu
et al.’s study (4). İnan et al. found overall infection
rates of 29.1% and 34.2 per 1000 patient days (12). In
a study investigating the nosocomial infection
surveillance of a center for 10 years between 1997 and
2006, infection rates were found 20.8 per 1000 patient
days in the ICU, which was also similar to our rates
(13).
In this study, most common device-associated
infection was VAP (49.5%), followed by CA-UTI
(31.5%) and CA-BSI (18.9%). This was similar to the
results in other developing countries; Rosenthal et al.
found that the most common infection was VAP
(41%, n = 1277), followed by CA-UTI (30%, n = 930)
and CA-BSI (29%, n = 888) (11). In the Turkish
branch of this study, VAP consisted 47.4% of all
IDAIs, followed by CA-BSI with 30.4% and CA-UTI
with 22.2% where VAP ratio was similar and CA-BSI
ratio was significantly higher than our study (4). İnan
et al. also showed a similar distribution of IDAIs
38.7% VAP, 38.7% CA-UTI, and 22.6% CA-BSI (12).
Doğru et al. found a similar distribution; VAP was
53.6% where CA-BSI and CA-UTI were 25.9% and
21.5%, respectively (14).
There was a decreasing trend in IDAI rates from
2006 to 2009 (Table 1) with overall VAP rate of 23.11
per 1000 ventilator days, CA-BSI rate of 8.92 per 1000
catheter days, and CA-UTI rate of 9.24 per 1000
catheter days. When these rates were compared with
those in National Healthcare Safety Network (NHSN)
report, all IDAI rates were over the 90th percentile
while device utilization ratios were between the 25th
and 50th percentiles, which means infection control
practices should be more intensively applied (15).
Similarly, when compared with German Nosocomial
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Table 2. Distribution of the microorganisms causing invasive device-associated infections.
2006
N /%

2007
N /%

2008
N /%

2009
N /%

Total
N /%

Acinetobacter baumannii

153 / 28.4

219 / 25.9

235 / 23.2

228 / 26.1

835 / 25.5

Pseudomonas aeruginosa

71 / 13.2

115 / 13.6

144 / 14.2

135 / 15.5

465 / 14.2

Stenotrophomonas maltophilia

18 / 3.3

18 / 2.1

11 / 1.1

5 / 0.6

52 / 1.6

Burkholderia cepacia

2 / 0.4

3 / 0.4

9 / 0.8

Pseudomonas spp

1 / 0.2

6 / 0.7

7 / 0.7

Acinetobacter spp.

4 / 0.5

14 / 0.4
16 / 1.8

30 / 0.9

8 / 0.9

12 / 0.4

Escherichia coli

41 / 7.6

71 / 8.4

92 / 9.1

75 / 8.6

279 / 8.5

Klebsiella pneumoniae

30 / 5.6

83 / 9.8

102 / 10.1

65 / 7.4

280 / 8.6

Enterobacter cloacae

6 / 1.1

11 / 1.3

14 / 1.4

15 / 1.7

46 / 1.4

Morganella morganii

3 / 0.6

3 / 0.3

3 / 0.3

9 / 0.3

Serratia marcescens

3 / 0.6

7 / 0.8

18 / 1.8

9/1

37 / 1.1

Klebsiella oxytoca

2 / 0.4

4 / 0.5

7 / 0.7

7 / 0.8

20 / 0.6

Citrobacter spp.

1 / 0.2

4 / 0.5

4 / 0.4

4 / 0.5

13 / 0.4

Proteus spp.

1 / 0.2

6 / 0.7

8 / 0.8

8 / 0.9

23 / 0.7

2/

2 / 0.2

15 / 1.7

19 / 0.6

Other gram negatives
Gram negatives

2134 / 65.3

Enterococcus faecium

21 / 3.9

46 / 5.4

39 / 38

42 / 4.8

148 / 4.5

Enterococcus faecalis

9 / 1.7

18 / 2.1

27 / 2.7

24 / 2.8

78 / 2.4

Enterococcus gallinarum/casseliflavus

2 / 0.4

1 / 0.1

1 / 0.1

3 /0.3

7 / 0.2

Enterococcus other

3/ 0.6

1 / 0.1

3 / 0.3

1 / 0.1

8 / 0.2

Staphylococcus aureus

77 / 14.3

66 / 7.8

78 / 7.7

39 / 4.5

260 / 8

Coagulase negative staphylococci

19 / 3.5

23 / 2.7

47 / 4.6

45 / 5.2

134 / 4.1

5/ 0.9

14 / 1.6

14 / 1.4

10 / 1.2

43 / 1.3

2 / 0.2

2 / 0.1

Streptococcus spp.
Other gram positives
Gram positives

680 / 20.8

Candida albicans

33 / 6.1

54 / 6.4

38 / 3.8

37 / 4.2

162 / 5

Candida glabrata

9 / 1.7

16 / 1.9

27 / 2.7

10 / 1.2

62 / 1.9

Candida tropicalis

6 / 1.1

18 / 2.1

33 / 3.3

16 / 1.8

73 / 2.2

Candida parapsilosis

5 / 0.9

16 / 1.9

33 / 3.3

31 / 3.6

85 / 2.6

Candida kefyr

5 / 0.6

4 / 0.4

Candida krusei

8 / 1.0

Other Candida spp.

16 / 3.0

7 / 0.8

9 / 0.3
8 / 0.2

14 / 1.4

19 / 2.2

Candida
Total

56 / 1.7
455 / 13.9

539 / 100

846 / 100

1012 / 100

872 / 100

3269 / 100

141

Invasive device-associated infections of a center

Table 3. Distribution of resistance patterns of etiological agents through 2006 and 2009.
2006
% (n)

2007
% (n)

2008
% (n)

2009
% (n)

P value*

Pseudomonas aeruginosa
meropenem R
amikacin R
ciprofloxacin R
piperacillin-tazobactam R

49.3 (35)
45.7 (32)
59.2 (42)
49.3 (35)

64.3 (73)
66.1 (74)
54 (61)
38.7 (43)

67.9 (95)
26.8 (38)
49.6 (70)
46.1 (65)

57.5 (77)
28.6 (38)
45.7 (59)
69 (89)

>0.05
<0.001
>0.05
<0.001

Acinetobacter baumannii
meropenem R
amikacin R
tobramycin R

44 (66)
86 (129)
27.1 (41)

71.9 (156)
82.5 (174)
37.4 (80)

85.2 (195)
51.3 (118)
70.9 (161)

90.8 (206)
63.4 (144)
49.3 (101)

<0.001
<0.001
<0.001

Enterococus spp.
ampicillin R
vancomycin R

62.9 (22)
22.8 ( 8)

82.5 (52)
21.7 (13)

55.7 (38)
34.3 (24)

68.6 (48)
31.4 (22)

>0.05
>0.05

MRSA rate

89.6 (69)

93.6 (58)

84.42 (65)

61.8 (21)

<0.001

ESBL rate
Escherichia coli
Klebsiella pneumonae

70.7 (29)
56.7 (17)

53.5 (38)
62.6 (52)

45.6 (42)
55.9 (57)

64.6 (42)
66.7 (50)

>0.05
>0.05

R: resistance
*: trend analysis is performed

Infection Surveillance System (KISS), all of the IDAI
rates in the present study were also over the 90th
percentile (16).

earlier than ours. Another reason can be the need for
more intense and complicated infection control
implementations for handling this kind of infection.

Despite these unpromising figures, when
compared with developing countries’ and some
European data, our IDAI rates were not very high.
VAP rates were similar to the rates in the INICC study
and even better than some of the countries’ (overall
rate of 24.1 and range between 10.0 and 52.7 cases per
1000 ventilator days) (11). In a Dutch study VAP rate
was found to be 25 infections per 1000 ventilator days
(17). Some other studies reported such rates as 20.4
and 19.3 infections per 1000 ventilator days by Orsi
et al. from Italy (18), 21 infections per 1000 patient
days by Lizan-Garcia et al. from Spain (19), and 12.1
infections per 1000 ventilator days by Dima et al from
Greece (20). The reason for higher rates in Spanish
and Italian studies may be the study periods’ being

Limited number of Turkish studies also report
similar VAP rates; 26.5 infections per 1000 ventilator
days by Leblebicioğlu et al. in Turkish branch of
INICC (4), 20.76 infections per 1000 ventilator days
by İnan et al. (12), 22.6 infections per 1000 ventilator
days by Erdem et al. (21), 27.1 infections per 1000
ventilator days by Doğru et al. (14), and a higher rate
of 59.7 infections per 1000 ventilator days from a
small university hospital by Turgut et al., saying that
smaller hospitals can also have higher nosocomial
infection rates, emphasizing the urgent need of the
implementation of infection control guidelines (22).
According to our national surveillance data, our VAP
rates were generally between the 25th and 50th
percentiles (23).
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In contrast with the NHSN report, when
compared with those in other developing country and
some European rates, CA-BSI rates in the present
study were considerably low; 12.5 infections per 1000
catheter days (ranging between 7.8 and 18.5
infections) in INICC study (11), 19.1 and 16.6
infections per 1000 catheter days in the study by Orsi
et al. (18), 12.1 infections per 1000 catheter days from
Greece (20), 30 infections per 1000 catheter days from
Spain (19), 30.3 infections per 1000 catheter days
from Argentina by Roshental et al. (24), and 12.0
infections per 1000 catheter days from Israeli by
Finkelstein et al. (25).
The Turkish data available on CA-BSI were very
diverse; in the biggest study by Leblebicioğlu et al.
(Turkish branch of INICC) CA-BSI rate was found as
17.6 infections per 1000 catheter days (4); İnan et al.
(12), Yılmaz et al. (26), and Doğru et al. (14) found
similar rates to ours (9.69, 9.6, and 11.8 infections per
1000 catheter days, respectively), whereas the study
by Turgut et al. showed relatively low rates (4.1
infections per 1000 catheter days), probably because
of lower device utilization ratios (22). But considering
the biggest and the only multicenter study and
national surveillance data, the rates in the present
study appear to be similar to and lower than Turkish
average, possibly because of the education given in
our center and infection control practices in this field,
Surveillance is the first step to decrease health-care
associated infections. In our setting starting with
surveillance we stressed the importance of infection
control, but there are still some institutional and
national deficiencies. There are no standards for
invasive procedures including catheter insertion,
ventilator associated procedures, sterilization, and
disinfection. Understaffing is another important
factor for high infection rate. Nurse and cleanup
personnel shortage at the night shifts and weekends
could also be another source. What is more, the
government does not provide enough support for
infection control at university hospitals (23,27-29). All
these may account for the figures in infection control
similar to or slightly better than those in some
countries but not as good as those in developed
countries.
CA-UTI rates were similar with the rates in other
developing country, ranging between 1.7 and 12.8

infections per 1000 catheter days in the INICC study,
and 1.3 and 9 infections per 1000 catheter days in
different European countries; whereas rates in
individual developing countries were significantly
higher (11,18-20). Turkish data were similar in this
case, possibly because of CA-UTI’s being the first area
of improvement in infection control practices in most
of the centers, and because of its being relatively easier
to lower this kind of infection (4,12,14,22). These
relatively low rates of CA-UTI can also be the result of
our educational and infection control programs in our
institution. However, the absence of routine usage of
closed catheterization systems, lack of adequate
number of trained personnel, and limited resources
for infection control practices make the difference
with the developed countries.
Microorganisms causing VAP in the INICC study
was similar to ours with small differences, i.e. P.
aeruginosa, Enterobacteriaceae, A. baumannii, and S.
aureus being the leading causative agent (11). In a
study from Turkey, P. aeruginosa was the leading
microorganism, followed by Acinetobacter spp. and
Candida spp. (14). Studies from Europe were
generally similar except for a small number (Table 4).
The major causative agents in CA-BSIs were CNS
and Acinetobacter spp. in most of the studies (Table
4). S. aureus, P. aeruginosa, and Enterococcus spp. were
also frequently isolated from these kinds of infections
in the majority of the hospitals. S. maltophilia also
attracted attention in one of the studies by an
incidence rate of 10.9% (18).
CA-UTIs were mainly caused by Candida species
in most of the centers in Turkey (12,14,22), but the
causative distribution of the European hospitals were
quite different and diverse (Table 4) (18,20). The
difference from Europe may be due to the
unnecessary and prolonged urinary catheterization,
use of broad spectrum antibiotics in consequence of
resistance, prolonged hospitalization in ICU, and
underlying diseases like diabetes mellitus, cancer, and
septicemia.
High resistance rates among gram negative
bacteria as well as gram positive bacteria were one of
the remarking results of our study. When we compare
the results with NNIS data where MRSA, VRE,
ciprofloxacin, and carbapenem resistant P. aeruginosa,
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Table 4. Comparison of the most frequent microorganisms isolated from infection sites in selected studies and the present study.
Study

VAP

CA-BSI

CA-UTI

Present study

A.baumannii 40%
P.aeruginosa 18.8%
S.aureus 13.8%
K.pneumoniae 9.1%

A.baumannii 19.1%
E.faecium 10.6%
CNS 8.4%
S.aureus 8.4%

Candida spp. 31.6%
E.coli 17.9%
Enterococcus spp. 8.9%
K.pneumoniae 7.8%

Dima et al. (20)
Greece, 2007

Acinetobacter spp. 28%
Pseudomonas spp. 23.2%
S.aureus 13.6%

CNS 25.4%
Acinetobacter spp. 20.7%
K.pneumoniae 14.5%
Enterococcus spp. 13%

Streptococcus spp. 17%
Enterococcus spp. 17%
Pseudomonas spp. 14.9%
Klebsiella spp. 17.8%

*Orsi et al. (18)
Italy, 2005

P.aeruginosa 38.3%
S.aureus 22.3%
A.baumannii 11.7%

CNS 21.9%
P.aeruginosa 17.2%
S.aureus 17.2%
S. maltophilia 10.9%

P.aeruginosa 63.6%

Rosenthal et al. (11)
INICC, 2006

Enterobacteriaceae 26%
P.aeruginosa 26%
S.aureus 22%
Acinetobacter spp. 20%

Enterobacteriaceae 27%
S.aureus 25%
CNS 18%
Acinetobacter spp. 13%

Enterobacteriaceae 42%
Candida spp. 30%
P.aeruginosa 13%

İnan et al. (12)
Turkey, 2006

Pseudomonas spp. 38.3%
Acinetobacter spp. 27.3%
Klebsiella spp. 13.4%

CNS 20%
Acinetobacter spp. 13.4%
S.aureus 13.1%
Enterococcus spp. 12.8%

Candida spp. 37.1%
Pseudomonas spp. 16.5%
E.coli 12.1%

Turgut et al. (22)
Turkey, 2008

Acinetobacter spp. 26%
Pseudomonas spp. 24%
E.coli 11%

CNS 50%
S.aureus 40%

Candida spp. 41%
E.coli 22%
Pseudomonas spp. 10%

Doğru et al. (14)
Turkey, 2010

P.aeruginosa 25%
Acinetobacter spp. 23%

CNS 26.5%
Pseudomonas spp. 16.3%

E.coli 38%
Candida spp. 41%

**EPIC study (32)
Europe, 1996

Enterobacteriaceae 34.4%
S. aureus 30.1%
P. aeruginosa 28.7%
CNS 19.1%
Fungi 17.1%

**HELICS-ICU (33)
Europe, 2007

S. aureus 19.6%
P. aeruginosa 18.8%
E. coli 8.5%
Klebsiella spp. 8.1%

VAP: Ventilator associated pneumonia, CA-BSI: Catheter associated blood stream infection,
CA-UTI: Catheter-associated urinary tract infection, CNS: coagulase negative staphylococci
*The mentioned infections are not device associated. They are nosocomial pneumonia, blood stream infection, and urinary tract infection.
** The mentioned infections are not device associated. Given isolates represent overall results.
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rates were 52.4%, 13.9%, 34.8%, and 19.1%,
respectively, all our rates were very high and over the
90th percentile (1). Resistance data extracted from the
German Nosocomial Infection Surveillance System
for ICUs showed lower rates; MRSA and VRE rates
were 28.8% and 0.9%, respectively (30). Other
resistance surveillance studies from Europe and
America also showed significantly lower resistance
rates than ours (31-33).
When compared with the rates in developing
countries, our rates were similar except for the high
VRE rates in our study. In the INICC study MRSA,
ceftriaxone-resistant
Enterobactericeae,
Ciprofloxacin-resistant P. aeruginosa, and VRE rates
were 84%, 55%, 59%, and 5%, respectively (11). A
study from Thailand also reported similar resistance
rates: MRSA, imipenem resistant P. aeruginosa,
ceftazidime-resistant A. baumannii, third generation
cephalosporine resistant K. pneumoniae, and
ciprofloxacin-resistant E. coli rates were 68.8%, 30.9%,
68.8%, 44.6%, and 38.3%, respectively (34).
There are only few Turkish studies reporting the
resistance data of IDAIs. One is the report of Turkish
branch of the INNIC by Leblebicioğlu with an MRSA
rate of 89.2%, and ceftriaxone, ceftazidime, and
piperacillin-tazobactam resistant Enterobactericeae
rates of 48.2%, 52.0%, and 33.2%, respectively.
Imipenem and piperacilin-tazobactam resistant P.
aeruginosa rates were 38.7% and 30.0%, whereas VRE
and piperacilin-tazobactam resistant A. baumannii
rates were 1.9% and 87.1%, respectively (4). A VAP
study from İstanbul, Turkey, reports ceftazidime,
imipenem, ciprofloxacin, and amikacin resistant A.
baumannii rates of 90%, 64%, 80%, and 43%, and
ceftazidim, piperacilin-tazobactam, imipenem,
ciprofloxacin, and amikacin resistant P. aeruginosa
rates were 59%, 41%, 32%, 62%, and 16%, respectively
(35). According to recently published national data,
our rates were over the 90th percentile, except MRSA,
which decreased significantly in 2009 to the 50th-75th
percentiles. All these high resistance rates were linked
to lack of infection control practices and the decrease

in MRSA rates was thought to be the result of
decreased cross-contamination via decreased S.
aureus rates among causatives (from 14.5% in 2006 to
4.5% in 2009).
The remarkable resistance rates among gram
negative and gram positive bacteria in our institute,
particularly the VRE rate, represent the lack of
infection control practices along with antibiotic
control policies. Since 2006, when the national
surveillance system was established and surveillance
became mandatory in this country, all of the hospitals
around Turkey have been reporting their hospital
infection rates to the Ministry of Health. However, the
outcome of infection control practices was not as
good as expected. Possible reasons for this may be the
lack of administrative and financial support, lack of
feedback, personnel shortage, patient overload due to
the fact that it is a reference and training hospital in
this region, ineffective compliance to infection control
practices, and lack of adequate legislative control. The
government also started quality control studies
among public hospitals. Unfortunately university
hospitals are not included in this implementation and
are left to their fate, which can be another cause
contributing to the high IDAI and resistance rates.
In conclusion, our hospitals’ IDAI rates were
similar with the rates in this country and those in
neighboring countries but significantly higher than
the rates in developed countries. Regarding the
increase at resistance rates to most of the available
antibiotics, there is an urgent need for implementing
infection control measures and more effective
antibiotic control policies.
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